Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
Phase 3
Completed
- Conditions
- Dyslipidemia Patients With Hypertension
- Interventions
- Drug: D013, D326, D337Drug: placebo of D013, D326, D337Drug: D013, placebo of D326, placebo of D337
- Registration Number
- NCT04312698
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Brief Summary
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis.
- Subjects who agreed to participate in this clinical trial voluntarily.
Read More
Exclusion Criteria
- Subjects who were satisfied specific blood pressure levels that measured at screening period.
- Subjects who were satisfied specific lipid levels that measured at screening period.
- Subjects who cannot participate in a clinical trial based on the PI's judgment.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental Group 1 D013, D326, D337 - Comparator Group 1 placebo of D013, D326, D337 - Comparator Group 2 D013, placebo of D326, placebo of D337 -
- Primary Outcome Measures
Name Time Method Change rate from baseline in LDL-C 8 weeks after drug administrations Compare experimental group 1 with comparator group 1
Change from baseline in MSSBP 8 weeks after drug administrations Compare experimental group 1 with comparator group 2
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Yonsei University Medical Center Severance Hospital
🇰🇷Seoul, Korea, Republic of